Camizestrant
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for Camizestrant, covering 2025-03-25 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer [Phase 3]